Reply to: “Is uracil enough for effective pre-emptive DPD testing?”-Reference-Cited by-同舟云学术

Reply to: “Is uracil enough for effective pre-emptive DPD testing?”

Published:2024-08-15 Issue: Volume: Page:
ISSN:1434-6621
Container-title:Clinical Chemistry and Laboratory Medicine (CCLM)
language:en
Short-container-title:

Author:

Thomas Fabienne¹²³^ORCID,Launay Manon²⁴,Raymond Laure³⁵,Guitton Jérôme²⁶⁷,Loriot Marie-Anne³⁸⁹,Chatelut Etienne¹²,Haufroid Vincent³¹⁰,Etienne-Grimaldi Marie-Christine²³¹¹

Affiliation:

1. Oncopole Claudius Regaud , Institut Universitaire du Cancer and CRCT, University of Toulouse, Inserm , Toulouse , France

2. French Clinical Oncopharmacology Group (GPCO)-UNICANCER , Paris , France

3. Francophone Network of Pharmacogenetics (RNPGx) , Paris , France

4. Service de médecine intensive et réanimation médicale et Centre Régional de Pharmacovigilance , CHU de Saint-Etienne , Saint-Etienne , France

5. Département de génétique , Laboratoire Eurofins Biomnis , Lyon , France

6. Laboratoire de Biochimie et Toxicologie, Centre Hospitalier Lyon-Sud , Hospices Civils de Lyon , Pierre-Bénite , France

7. Laboratoire de Toxicologie, ISPB, Faculté de Pharmacie , Université Lyon 1, Université de Lyon , Lyon , France

8. Department of Clinical Chemistry, Assistance Publique Hôpitaux de Paris-Centre , Hôpital Européen Georges-Pompidou , Paris , France

9. INSERM UMR-S1138, Centre de recherches des Cordeliers , Université of Paris Cité , Paris , France

10. Brussels and Clinical Chemistry Department, Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institut de recherche expérimentale et clinique , UClouvain, Cliniques Universitaires Saint-Luc , Brussels , Belgium

11. Oncopharmacology Laboratory , Centre Antoine Lacassagne , Nice , France

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/cclm-2024-0889/pdf

Reference13 articles.

1. Heersche, N, Matic, M, Mathijssen, RHJ, Coenen, MJH, van Schaik, RHN. Is uracil enough for effective pre-emptive DPD testing? Clin Chem Lab Med 2024. https://doi.org/10.1515/cclm-2024-0742.

2. Launay, M, Raymond, L, Guitton, J, Loriot, M-A, Chatelut, E, Haufroid, V, et al.. Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis. Clin Chem Lab Med 2024. https://doi.org/10.1515/cclm-2024-0317.

3. CPIC dosing guideline for fluorouracil and DPYD [Internet]. [cited 2015 Jul 7]. Available from: https://www.pharmgkb.org/guideline/PA166122686.

4. Arrivé, C, Fonrose, X, Thomas, F, Roth, G, Jacquet, E, Brice, A, et al.. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: what are the explanatory factors? Br J Clin Pharmacol 2023;89:2446–57. https://doi.org/10.1111/bcp.15715.

5. Royer, B, Launay, M, Ciccolini, J, Derain, L, Parant, F, Thomas, F, et al.. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping. ESMO Open 2023;8:101577. https://doi.org/10.1016/j.esmoop.2023.101577.